Getsinger Peter W sold $4.7M of AGX

Getsinger Peter W sold 6,728 shares of ARGAN INC (AGX) at an average of $705.78 ($699.00–$708.65, $4.75M total) across 2 trades over 2026-06-16 to 2026-06-17.

Original reporting
SEC EDGAR · Getsinger Peter W
Published Jun 17, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AGX
Neutral
medium confidence
Mentioned
$AGX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGXNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 6,728 shares (about $4.75M) with trades on 6/16–6/17 and holdings after sale of 4,880 shares; no 10b5-1 plan is indicated.

02

Market read

Traders may monitor AGX for sentiment/flow effects from insider selling, but the filing alone doesn’t provide a fundamental catalyst.

03

What to watch

Insider sales often have weak predictive power without accompanying changes in guidance, contracts, or ownership concentration; also, the article doesn’t state whether other insiders/large holders acted similarly.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-17; insider sale disclosed for trades dated 2026-06-16 to 2026-06-17.

Background

The article is an SEC Form 4 insider transaction disclosure for Argan Inc (AGX) by director Peter W Getsinger.

Company-level read

Ticker impact

$AGXNeutralMedium confidence
Context

Argan Inc director Peter W Getsinger sold 6,728 shares in open-market transactions for about $4.75M, per a new SEC Form 4.

Expected impact

Modest near-term negative/neutral bias; no clear directional catalyst beyond insider-sale optics.

Evidence & confidence

The filing is a primary-source Form 4 showing size ($4.75M) and timing (6/16–6/17) but provides no stated reason, and it explicitly notes no 10b5-1 plan.

Market effects

Minimal—this is company-specific insider activity with no sector-wide regulatory or earnings signal.

None indicated; disclosure is US-focused and not tied to broader regional macro events.

Low—no international deal, guidance, or regulatory action is described.

Counterpoint

The sale may be for diversification, taxes, or pre-planned liquidity needs; absence of a 10b5-1 plan doesn’t automatically imply negative fundamentals.

Key entities

  • Argan Inc

    Subject of the Form 4 insider sale disclosure; director Peter W Getsinger sold shares totaling ~$4.75M.

  • Peter W Getsinger

    Director who executed the open-market sales; holdings after transaction reported as 4,880 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AGXMed

Silver X Files NI 43-101 Technical Report for the Updated Nueva Recuperada Mineral Resource: 10.4 Mt Measured and Indicated at 202 g/t AgEq (67.3 Moz AgEq) and 21.6 Mt Inferred at 260 g/t AgEq (184.3 Moz AgEq)

Silver X Mining Corp. (AGX) filed an updated NI 43-101 technical report for its Nueva Recuperada project in Peru, showing increased mineral resources. Measured and Indicated resources total 10.4 Mt with 67.3 Moz AgEq, up 107% from the previous estimate. Inferred resources total 21.6 Mt with 184.3 Moz AgEq. The report includes revisions from the September 22, 2026 news release, with no change in tonnage or classification. The company plans to expand its mining operations and plant capacity.

$AGXMedAI 8/10

Argan’s (AGX) Power Boom Comes With A Margin Catch

Argan (AGX) reported record Q2 revenue of $384.0M (+61.5% YoY) and net income of $53.3M, driven by its Power segment. Gross margin slipped to 19.3%, and backlog decreased to $2.5B. The company is debt-free with $1.03B in cash, returning $51.7M to shareholders. Management expects new projects but faces regulatory challenges and margin compression.

$AGXMed

Argan (AGX) Q2 2027 Earnings Call Transcript

Argan (AGX) reported Q2 2027 revenue of $384.0M, up 61.5%, with net income of $53.3M ($3.76 per diluted share). Power segment revenue grew 53% YoY to $301M, while Industrial segment revenue rose 111% to $76M. Consolidated backlog decreased to $2.5B. The company plans to complete a new fabrication facility in North Carolina by Q3 2027.